Advertisement

Efficacy and Safety of Deep Sedation in Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma

  • Koki SatoEmail author
  • Nobuhito Taniki
  • Ryo Kanazawa
  • Motonori Shimizu
  • Shigeto Ishii
  • Hideko Ohama
  • Masashi Takawa
  • Hiroaki Nagamatsu
  • Yasuharu Imai
  • Shuichiro Shiina
Original Research

Abstract

Introduction

Radiofrequency ablation (RFA) has been accepted as safe and effective for treating early-stage hepatocellular carcinoma (HCC). However, it often causes severe pain. Therefore, in this study, we performed RFA under deep sedation and investigated its efficacy and safety.

Methods

We conducted a retrospective study including 511 HCC patients who received approximately 886 RFA treatments between December 2014 and November 2016 at our institution. Respiratory depression was defined as oxygen saturation of below 90%; and severe body movement was defined as movement caused by pain, which was managed by lowering the power of the generator. Factors associated with respiratory depression and severe body movement were examined via univariate and multivariate regression analyses.

Results

Respiratory depression occurred in 15.3% of the patients and severe body movement in 26.5% of the patients. In the multivariate analysis, BMI (≥ 25 kg/m2, odds ratio [OR] = 1.75, P = 0.035) and longer ablation (≥ 10 min, OR = 2.59, P = 0.002) were significant respiratory depression-related factors. Male sex (OR = 2.02, P = 0.005), Child–Pugh class A (odds ratio = 1.96, P = 0.018), and longer ablation (≥ 10 min, OR = 3.03, P < 0.001) were significant factors related to severe body movement.

Conclusion

Deep sedation for RFA can be performed safely and effectively. Higher BMI and longer ablation were risk factors for respiratory depression and male sex, Child–Pugh class A, and longer ablation were independent predictors of severe body movement during RFA under deep sedation.

Keywords

Deep sedation Hepatocellular carcinoma Percutaneous radiofrequency ablation Respiratory depression Severe body movement 

Notes

Acknowledgements

We thank Hideki Hisayasu for providing technical assistance and the participants of the study.

Funding

No funding or sponsorship was received for this study or the publication of this article. The article processing charges were funded by the authors. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the analysis.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Koki Sato, Nobuhito Taniki, Ryo Kanazawa, Motonori Shimizu, Shigeto Ishii, Hideko Ohama, Masashi Takawa, Hiroaki Nagamatsu, Yasuharu Imai, and Shuichiro Shiina have nothing to disclose.

Compliance with Ethics Guidelines

All procedures performed in studies involving human participants were in accordance with the ethical standards of Hospital Ethics Committee Juntendo University Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The requirement for written informed consent was waived.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality world wide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefGoogle Scholar
  2. 2.
    Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107(4):569–77.CrossRefGoogle Scholar
  3. 3.
    Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103(6):1201–9.CrossRefGoogle Scholar
  4. 4.
    Lee DH, Lee JM, Lee JY, et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis. Radiology. 2014;270(3):900–9.CrossRefGoogle Scholar
  5. 5.
    Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234(3):961–7.CrossRefGoogle Scholar
  6. 6.
    Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226(2):441–51.CrossRefGoogle Scholar
  7. 7.
    Mulier S, Mulier P, Ni Y, et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg. 2002;89(10):1206–22.CrossRefGoogle Scholar
  8. 8.
    Shiina S, Sato K, Tateishi R, et al. Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery. Can J Gastroenterol Hepatol. 2018;2018(3):4756147.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Canale M, Ulivi P, Foschi FG, et al. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. Crit Rev Oncol Hematol. 2018;129:44–53.CrossRefGoogle Scholar
  10. 10.
    Lee S, Rhim H, Kim YS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinomas: factors related to intraprocedural and postprocedural pain. AJR Am J Roentgenol. 2009;192(4):1064–70.CrossRefGoogle Scholar
  11. 11.
    Yokoyama K, Ikeda O, Kawanaka K, et al. Pain control in patients with hepatocellular carcinoma treated by percutaneous radiofrequency ablation: comparison of the efficacy of one-shot and continuous intravenous fentanyl delivery. Acta Radiol. 2014;55(10):1219–25.CrossRefGoogle Scholar
  12. 12.
    Hori M, Tanaka M, Suzuki Y, et al. Periprocedural pain of radiofrequency ablation for hepatocellular carcinoma. Gastroenterol Nurs. 2011;34(2):129–34.CrossRefGoogle Scholar
  13. 13.
    Cohen LB, Delegge MH, Aisenberg J, et al. AGA Institute review of endoscopic sedation. Gastroenterology. 2007;133(2):675–701.CrossRefGoogle Scholar
  14. 14.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36.CrossRefGoogle Scholar
  15. 15.
    Kondo Y, Yoshida H, Tateishi R, Shiina S, Kawabe T, Omata M. Percutaneous radiofrequency ablation of liver cancer in the hepatic dome using the intrapleural fluid infusion technique. Br J Surg. 2008;95(8):996–1004.CrossRefGoogle Scholar
  16. 16.
    Kondo Y, Yoshida H, Shiina S, Tateishi R, Teratani T, Omata M. Artificial ascites technique for percutaneous radiofrequency ablation of liver cancer adjacent to the gastrointestinal tract. Br J Surg. 2006;93(10):1277–82.CrossRefGoogle Scholar
  17. 17.
    Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. Radiology. 2014;273(1):241–60.CrossRefGoogle Scholar
  18. 18.
    Scholer SG, Schafer DF, Potter JF. The effect of age on the relative potency of midazolam and diazepam for sedation in upper gastrointestinal endoscopy. J Clin Gastroenterol. 1990;12(2):145–7.CrossRefGoogle Scholar
  19. 19.
    Bell GD, Spickett GP, Reeve PA, Morden A, Logan RF. Intravenous midazolam for upper gastrointestinal endoscopy: a study of 800 consecutive cases relating dose to age and sex of patient. Br J Clin Pharmacol. 1987;23(2):241–3.CrossRefGoogle Scholar
  20. 20.
    Berzin TM, Sanaka S, Barnett SR, et al. A prospective assessment of sedation-related adverse events and patient and endoscopist satisfaction in ERCP with anesthesiologist-administered sedation. Gastrointest Endosc. 2011;73(4):710–7.CrossRefGoogle Scholar
  21. 21.
    Yang JF, Farooq P, Zwilling K, Patel D, Siddiqui AA. Efficacy and safety of propofol-mediated sedation for outpatient endoscopic retrograde cholangiopancreatography (ERCP). Dig Dis Sci. 2016;61(6):1686–91.CrossRefGoogle Scholar
  22. 22.
    Rhim H. Complications of radiofrequency ablation in hepatocellular carcinoma. Abdom Imaging. 2005;30(4):409–18.CrossRefGoogle Scholar
  23. 23.
    Wang Y, Deng T, Zeng L, et al. Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a meta-analysis. Hepatol Res. 2016;46(1):58–71.CrossRefGoogle Scholar
  24. 24.
    Teratani T, Yoshida H, Shiina S, et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 2006;43(5):1101–8.CrossRefGoogle Scholar
  25. 25.
    Joung KW, Choi SS, Jang DM, et al. comparative effects of dexmedetomidine and propofol on US-guided radiofrequency ablation of hepatic neoplasm under monitored anesthesia care: a randomized controlled Study. Medicine (Baltimore). 2015;94(32):e1349.CrossRefGoogle Scholar
  26. 26.
    Kuo YH, Chung KC, Hung CH, Lu SN, Wang JH. The impact of general anesthesia on radiofrequency ablation of hepatocellular carcinoma. Kaohsiung J Med Sci. 2014;30(11):559–65.CrossRefGoogle Scholar
  27. 27.
    Shamim F, Asghar A, Tauheed S, et al. Radiofrequency ablation of hepatocellular carcinomas: a new spectrum of anesthetic experience at a tertiary care hospital in Pakistan. Saudi J Anaesth. 2017;11(1):21–5.CrossRefGoogle Scholar
  28. 28.
    Qadeer MA, RocioLopez A, Dumot JA, Vargo JJ. Risk factors for hypoxemia during ambulatory gastrointestinal endoscopy in ASA I-II patients. Dig Dis Sci. 2009;54(5):1035–40.CrossRefGoogle Scholar
  29. 29.
    Qadeer MA, Lopez AR, Dumot JA, Vargo JJ. Hypoxemia during moderate sedation for gastrointestinal endoscopy: causes and associations. Digestion. 2011;84(1):37–45.CrossRefGoogle Scholar
  30. 30.
    Fisher L, Fisher A, Thomson A. Cardiopulmonary complications of ERCP in older patients. Gastrointest Endosc. 2006;63(7):948–55.CrossRefGoogle Scholar
  31. 31.
    Ongiem A, Siriussawakul A, Wangdee A, et al. Assessment of pain severity after radiofrequency ablation in patients with hepatocellular carcinoma. J Med Assoc Thai. 2016;99(5):572–7.PubMedGoogle Scholar
  32. 32.
    Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: drug disposition in old age. N Engl J Med. 1982;306(18):1081–8.CrossRefGoogle Scholar
  33. 33.
    Goldstein G. Pentazocine. Drug Alcohol Depend. 1985;14(3–4):313–23.CrossRefGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  • Koki Sato
    • 1
    Email author return OK on get
  • Nobuhito Taniki
    • 1
  • Ryo Kanazawa
    • 1
  • Motonori Shimizu
    • 1
  • Shigeto Ishii
    • 1
  • Hideko Ohama
    • 1
  • Masashi Takawa
    • 1
  • Hiroaki Nagamatsu
    • 1
  • Yasuharu Imai
    • 1
  • Shuichiro Shiina
    • 1
  1. 1.Department of GastroenterologyJuntendo University School of MedicineTokyoJapan

Personalised recommendations